AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%

Key details from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 2/3 study are as follows:
- The trial met its primary endpoint and key secondary endpoints with high statistical significance;
- Bamlanivimab and etesevimab together reduced COVID-19 events by 70% versus placebo (p=0.0004); and
- All deaths occurred in patients taking the placebo. No deaths occurred in patients taking bamlanivimab and etesevimab together.